$11.8499
-0.1601[-1.33%]
At close: May 17
$11.8499
0[0.00%]
After Hours: 7:47PM EDT
Sage Therapeutics
(NASDAQ:SAGE)Latest News for Sage Therapeutics Stock (NASDAQ:SAGE)
Sage Therapeutics Stock (NASDAQ: SAGE)
Categories: All
Tuesday, May 14, 2024
Wednesday, May 01, 2024
Friday, April 26, 2024
- HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $25Benzinga Newsdesk - Apr 26, 2024, 2:19PM
- Goldman Sachs Maintains Neutral on Sage Therapeutics, Lowers Price Target to $19Benzinga Newsdesk - Apr 26, 2024, 12:06PM
- RBC Capital Maintains Sector Perform on Sage Therapeutics, Lowers Price Target to $15Benzinga Newsdesk - Apr 26, 2024, 11:56AM
- Truist Securities Maintains Hold on Sage Therapeutics, Lowers Price Target to $18Benzinga Newsdesk - Apr 26, 2024, 11:55AM
- Mizuho Maintains Neutral on Sage Therapeutics, Lowers Price Target to $18Benzinga Newsdesk - Apr 26, 2024, 9:14AM
- Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $17Benzinga Newsdesk - Apr 26, 2024, 8:56AM
- Needham Reiterates Hold on Sage TherapeuticsBenzinga Newsdesk - Apr 26, 2024, 5:29AM
Thursday, April 25, 2024
- Needham Reiterates Hold on Sage TherapeuticsBenzinga Newsdesk - Apr 25, 2024, 7:58AM
- Sage Therapeutics Expects Cash & Equivalents Plus Funding To Support Its Operations Into 2026; Expects ZULRESSO Revenues To Continue To Decrease Over TimeBenzinga Newsdesk - Apr 25, 2024, 6:40AM
- Sage Therapeutics Q1 2024 GAAP EPS $(1.80) Misses $(1.65) Estimate, Sales $7.902M Beat $5.658M EstimateBenzinga Newsdesk - Apr 25, 2024, 6:31AM
Wednesday, April 24, 2024
Friday, April 19, 2024
Thursday, April 18, 2024
- Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $19Benzinga Newsdesk - Apr 18, 2024, 9:19AM
- Oppenheimer Maintains Perform on Sage Therapeutics, Lowers Price Target to $17Benzinga Newsdesk - Apr 18, 2024, 9:00AM
- In-Depth Examination Of 9 Analyst Recommendations For Sage TherapeuticsBenzinga Insights - Apr 18, 2024, 8:00AM
- TD Cowen Maintains Buy on Sage Therapeutics, Lowers Price Target to $16Benzinga Newsdesk - Apr 18, 2024, 7:49AM
- Needham Reiterates Hold on Sage TherapeuticsBenzinga Newsdesk - Apr 18, 2024, 5:28AM
Wednesday, April 17, 2024
- Crude Oil Dips 3%; U.S. Bancorp Profit Tops ViewsAvi Kapoor - Apr 17, 2024, 2:34PM
- Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Apr 17, 2024, 1:36PM
- HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $28 Price TargetBenzinga Newsdesk - Apr 17, 2024, 1:25PM
- Wedbush Reiterates Neutral on Sage Therapeutics, Maintains $24 Price TargetBenzinga Newsdesk - Apr 17, 2024, 1:21PM
- Nasdaq Down Over 1%; Sage Therapeutics Shares PlungeAvi Kapoor - Apr 17, 2024, 12:44PM
- Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's DataVandana Singh - Apr 17, 2024, 12:41PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Apr 17, 2024, 12:31PM
- B of A Securities Downgrades Sage Therapeutics to Underperform, Lowers Price Target to $14Benzinga Newsdesk - Apr 17, 2024, 9:38AM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Apr 17, 2024, 8:08AM
- J B Hunt Transport Reports Downbeat Earnings, Joins ASML And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionAvi Kapoor - Apr 17, 2024, 8:07AM
- Sage Therapeutics shares are trading lower. The company announced topline results from Phase 2 PRECEDENT study of dalzanemdor for the treatment of people with mild cognitive impairment in Parkinson's Disease.Benzinga Newsdesk - Apr 17, 2024, 7:38AM
- Sage Therapeutics Announces Topline Results From Phase 2 PRECEDENT Study Of Dalzanemdor (SAGE-718) In The Treatment Of Mild Cognitive Impairment In Parkinson's DiseaseBenzinga Newsdesk - Apr 17, 2024, 6:33AM
Tuesday, March 26, 2024
Monday, March 11, 2024
Wednesday, February 28, 2024
Thursday, February 15, 2024
- These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 ResultsAvi Kapoor - Feb 15, 2024, 12:59PM
- HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Raises Price Target to $28Benzinga Newsdesk - Feb 15, 2024, 12:19PM
- RBC Capital Maintains Sector Perform on Sage Therapeutics, Raises Price Target to $26Benzinga Newsdesk - Feb 15, 2024, 10:53AM
Wednesday, February 14, 2024
- Sage Therapeutics shares are trading higher after the company reported better-than-expected Q4 revenue results.Benzinga Newsdesk - Feb 14, 2024, 11:06AM
- Sage Therapeutics' Year-end 2023 Cash, Cash Equivalents, And Marketable Securities Of $753M Will Support The Company's Operations Into 2026Benzinga Newsdesk - Feb 14, 2024, 6:33AM
- Sage Therapeutics Q4 EPS $(0.55) May Not Be Comparable To $(1.28) Estimate, Sales $77.97M Beat $60.98M EstimateBenzinga Newsdesk - Feb 14, 2024, 6:32AM
- Earnings Scheduled For February 14, 2024Benzinga Insights - Feb 14, 2024, 4:48AM